Literature DB >> 24627585

Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Uday C Ghoshal1, Deepakshi Srivastava1.   

Abstract

Irritable bowel syndrome (IBS) is a common condition characterized by abdominal pain or discomfort, bloating, and altered stool form and passage. Small intestinal bacterial overgrowth (SIBO) is a condition in which there is overgrowth of bacteria in small bowel in excess of 10⁵ colony forming units per milliliter on culture of the upper gut aspirate. Frequency of SIBO varied from 4%-78% among patients with IBS and from 1%-40% among controls. Higher frequency in some studies might be due to fallacious criteria [post-lactulose breath-hydrogen rise 20 PPM above basal within 90 min (early-peak)]. Glucose hydrogen breath test (GHBT) has a low sensitivity to diagnose SIBO. Hence, studies based on GHBT might have under-estimated frequency of SIBO. Therefore, it is important to analyze these studies carefully to evaluate whether the reported association between IBS and SIBO is over or under-projected. This review evaluates studies on association between SIBO and IBS, discordance between different studies, their strength and weakness including methodological issues and evidence on therapeutic manipulation of gut flora on symptoms of IBS.

Entities:  

Keywords:  Dysbiosis; Functional bowel disease; Glucose hydrogen breath test; Gut flora; Lactulose hydrogen breath test

Mesh:

Substances:

Year:  2014        PMID: 24627585      PMCID: PMC3949258          DOI: 10.3748/wjg.v20.i10.2482

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  95 in total

1.  Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome.

Authors:  Y Bouhnik; S Alain; A Attar; B Flourié; L Raskine; M J Sanson-Le Pors; J C Rambaud
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

Review 2.  Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.

Authors:  Michele Di Stefano; Gino Roberto Corazza
Journal:  Chemotherapy       Date:  2005       Impact factor: 2.544

3.  Fecal transplantation: beyond the aesthetic.

Authors:  Kartik Sampath; L Campbell Levy; Timothy B Gardner
Journal:  Gastroenterology       Date:  2013-09-19       Impact factor: 22.682

4.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

5.  Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?

Authors:  Brian E Lacy; Scott L Gabbard; Michael D Crowell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

6.  Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

Authors:  M Majewski; R W McCallum
Journal:  Adv Med Sci       Date:  2007       Impact factor: 3.287

7.  Lactulose hydrogen and [14C]xylose breath tests in patients with ileoanal anastomosis.

Authors:  J Santavirta
Journal:  Int J Colorectal Dis       Date:  1991-11       Impact factor: 2.571

8.  The degree of breath methane production in IBS correlates with the severity of constipation.

Authors:  Soumya Chatterjee; Sandy Park; Kimberly Low; Yuthana Kong; Mark Pimentel
Journal:  Am J Gastroenterol       Date:  2007-04       Impact factor: 10.864

9.  Simultaneous culture of saliva and jejunal aspirate in the investigation of small bowel bacterial overgrowth.

Authors:  I Hamilton; B W Worsley; I Cobden; E M Cooke; J G Shoesmith; A T Axon
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

Review 10.  Use and abuse of hydrogen breath tests.

Authors:  M Simrén; P-O Stotzer
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  33 in total

1.  Eluxadoline: a promising therapy that raises many questions.

Authors:  Brooks D Cash
Journal:  Transl Gastroenterol Hepatol       Date:  2016-09-28

Review 2.  Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician.

Authors:  Sara Iqbal; Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2016-09

3.  FFA2 activation combined with ulcerogenic COX inhibition induces duodenal mucosal injury via the 5-HT pathway in rats.

Authors:  Yasutada Akiba; Koji Maruta; Kazuyuki Narimatsu; Hyder Said; Izumi Kaji; Ayaka Kuri; Ken-Ichi Iwamoto; Atsukazu Kuwahara; Jonathan D Kaunitz
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-19       Impact factor: 4.052

4.  Short-chain fatty acid sensing in rat duodenum.

Authors:  Yasutada Akiba; Takuya Inoue; Izumi Kaji; Masaaki Higashiyama; Kazuyuki Narimatsu; Ken-ichi Iwamoto; Masahiko Watanabe; Paul H Guth; Eli Engel; Atsukazu Kuwahara; Jonathan D Kaunitz
Journal:  J Physiol       Date:  2015-02-01       Impact factor: 5.182

5.  Prevalence of abnormal lactose breath hydrogen tests in children with functional abdominal pain.

Authors:  Neha Garg; Srikanta Basu; Preeti Singh; Ruchika Kumar; Lokesh Sharma; Praveen Kumar
Journal:  Indian J Gastroenterol       Date:  2017-06-07

Review 6.  Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.

Authors:  Uday C Ghoshal; Kok-Ann Gwee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

7.  Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Binrui Chen; John Jae-Woo Kim; Yawen Zhang; Lijun Du; Ning Dai
Journal:  J Gastroenterol       Date:  2018-05-14       Impact factor: 7.527

Review 8.  Is irritable bowel syndrome an infectious disease?

Authors:  John Richard Thompson
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 9.  Enhancing High Value Care in Gastroenterology Practice.

Authors:  Michael Camilleri; David A Katzka
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-20       Impact factor: 11.382

Review 10.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.